A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD
A Multi-Center, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe Atopic Dermatitis
Sponsor: Connect Biopharm LLC
Listed as NCT05905133, this PHASE2 trial focuses on Atopic Dermatitis and remains ongoing. Sponsored by Connect Biopharm LLC, it has been updated 9 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Jan 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Oct 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Connect Biopharm LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baotou, China , Beijing, China , Changsha, China , Chengdu, China , Dongying, China , Fuzhou, China , Guangzhou, China , Haikou, China , Hangzhou, China , Jiangxi, China and 18 more locations